生命科学资讯

With Vivtex deal, Novo gains a chance at better oral obesity drugs

BreezeBio banks $60M to make more precise genetic medicines

Vir climbs on Astellas deal, study results for ‘masked’ T cell engager

Novo to cut GLP-1 drug prices; Palvella soars on study data

Novo, searching for a spark, spotlights new data for three-pronged obesity drug

Slate starts up with $130M and a headache drug from China

FDA fleshes out new roadmap for testing personalized therapies

Novo’s next-gen obesity shot fails to match Lilly drug in head-to-head study

Merck to split cancer, specialty drug businesses in leadership shakeup

Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy

All about cell therapy process characterization

Grail’s multi-cancer early detection test misses study goal

Supreme Court invalidates Trump tariffs based on emergency powers

Roche gets FDA decision date on closely watched breast cancer drug

Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi

AI is slashing jobs across industries. Will pharma be next?

Altesa, run by former Trump official, raises $75M for well-traveled lung drug

FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals

Lilly to pay CSL $100M to license monoclonal antibody targeting IL-6

FDA accepts BMS protein degrader for review; Disc rare disease drug rejected